Kapil Mishra, MD
Retina Specialist · Irvine, CANPI 1790149896
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 41.9% of the total.
Across 86 payments — averaging $178.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Dutch Ophthalmic, USA$2K
- Carl Zeiss Meditec, Inc.$2K
- Carl Zeiss Meditec USA, Inc.$1K
- Eyepoint US, Inc.$900
- Genentech USA, Inc.$523
- plus $3K from 17 others
Across 10 payments — averaging $189.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
What the payments were for
- Consulting fees$8,20053%
- Travel & lodging$1,0177%
- Food & beverage$6,12540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $6,428 |
| Dutch Ophthalmic, USA | 8 | $2,059 |
| Carl Zeiss Meditec, Inc. | 1 | $1,600 |
| Carl Zeiss Meditec USA, Inc. | 13 | $1,104 |
| Eyepoint US, Inc. | 1 | $900 |
| Genentech USA, Inc. | 4 | $523 |
| Regeneron Healthcare Solutions, Inc. | 7 | $497 |
| Apellis Pharmaceuticals, Inc. | 7 | $413 |
| Rxsight Inc | 2 | $276 |
| Alimera Sciences, Inc. | 3 | $235 |
| Astellas Pharma US Inc | 3 | $215 |
| ANI Pharmaceuticals, Inc. | 4 | $181 |
| Bausch & Lomb Americas Inc. | 2 | $174 |
| Genentech, Inc. | 2 | $141 |
| Coherus Oncology, Inc. | 1 | $112 |
| Alcon | 1 | $109 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Regeneron | 2 | $97 |
| Immunocore Limited | 3 | $88 |
| Dompe US, Inc. | 1 | $27 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Biogen | 1 | $22 |
| Boehringer Ingelheim | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$5,917
- EVA, combined machine$1,948
- ATLAS 500$1,600
- CIRRUS 6000 with AngioPlex$1,600
- CIRRUS HD-OCT$1,600
- CLARUS$1,600
- TISSUEBLUE$1,298
- YUTIQ$900
- VABYSMO$643
- RXSIGHT CONTACT LENS$276
- RXSIGHT INJECTOR CARTRIDGE$276
- RXSIGHT INJECTOR HANDPIECE$276
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$276
- EYLEA$240
- LUMERA 700$234
- LIGHT ADJUSTABLE LENS (LAL)$163
- ARTEVO 800$124
- Syfovre$121
- Izervay$114
- Iluvien$114
How this compares
$15,342 in reported general payments places this provider in the 75th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IlevroNepafenac | 23 | $8,511 |
| ProlensaBromfenac Sodium | 19 | $6,643 |
| Prednisolone Acetate | 141 | $3,981 |
| Valganciclovir Hcl | 11 | $1,870 |
| Difluprednate | 14 | $1,327 |
| Ketorolac Tromethamine | 82 | $1,038 |
| Brimonidine Tartrate | 18 | $628 |
| MoxifloxacinMoxifloxacin Hcl | 21 | $381 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $148 |
| Timolol Maleate | 19 | $85 |
| Latanoprost | 14 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $25 | $6,64319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 187 retina specialist providers in California.
Other retina specialist in Irvine
- Baruch KuppermannIrvine$1M
- Mitul MehtaIrvine$192K
- Andrew BrowneIrvine$82K
- Nadeem VaidyaIrvine$18K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
- Carlos Medina MendezSacramento$548K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.